Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk.
Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, Reid P, Liew DFL, Goulabchand R, Singh AG, Hughes GC, Pioro M, Sparks JA, Jarvik JG, Singh S, Liew JW, Singh N.
Sendaydiego X, et al. Among authors: singh s.
JAMA Netw Open. 2024 Nov 4;7(11):e2446336. doi: 10.1001/jamanetworkopen.2024.46336.
JAMA Netw Open. 2024.
PMID: 39565623